02 July 2025
Press
F-CRIN (French Clinical Research Infrastructure Network) has just approved six new national clinical research networks, bringing to 26 the total number of structures supported by this organization of excellence in French health research, whose national coordination unit is based in Toulouse. These thematic networks address major public health needs, in fields as varied as maternal health, intensive care, infectiology, mycobacterial infections, pneumology and amyloidosis. By integrating the scientific, operational and collaborative dynamics of F-CRIN, they will reinforce France's ability to structure high-level clinical research that is visible and attractive at international level, as close as possible to the needs of patients, caregivers and innovation.
Crédits : Adobe Stock
Supported by Inserm in association with a consortium including university hospitals (CHU), universities, industry and patient representatives, and financed by the French National Research Agency (ANR) and the Ministry of Health, F-CRIN is a national platform of excellence serving French clinical research.
With more than 1,500 professionals pooling their know-how, work and resources, F-CRIN helps to facilitate the implementation of academic or industrial clinical trials, reinforce the skills of professionals involved in clinical research, and boost the competitiveness and attractiveness of French clinical research internationally, in order to develop access to new therapeutic solutions. It is also the French interface for the European clinical research network ECRIN.
The organization, which has a national coordination unit based in Toulouse, already federates and supports 20 components: I-REIVAC (vaccinology), NS-PARK (Parkinson's disease and abnormal movements), CRISALIS (severe asthma), FCRIN4MS (multiple sclerosis), INI-CRCT (cardiorenal diseases), FORCE (nutrition, obesity and metabolic disorders), PEDSTART (pediatrics), INNOVTe (thromboembolic venous disease), FRCRNET (retinal pathologies), CRI-IMIDIATE (autoimmune and auto-inflammatory diseases), FACT (cardiovascular diseases), CRICS-TRIGGERSEP (resuscitation and sepsis), ACT4ALS-MND (amyotrophic lateral sclerosis and motor neurone disease), F-PSYNet (psychotic disorders), FRADEN (atopic dermatitis), StrokeLink (stroke), MUST (primary care). F-CRIN also supports the two national expertise networks OrphanDev (rare diseases) and TECH4HEALTH (medical devices), as well as a customized support platform offering the full range of services needed to conduct clinical trials (EUCLID).
Today, F CRIN is pleased to announce the accreditation of six new research and clinical investigation networks:
- F-MOM: network dedicated to preventing serious complications in pregnancy and improving the care of pregnant women.
- GRACE: network dedicated to research into amyloidosis (in particular cardiac amyloidosis), a rare and serious disease that progressively disrupts organ function.
- CONDOR: network dedicated to clinical trials on chronic obstructive pulmonary disease, a major, chronic, progressive, irreversible respiratory disease affecting the bronchi and lungs.
- FAMIREA: network dedicated to research into support for relatives of patients in intensive care, to better prevent psychological after-effects.
- Myco-NET: network dedicated to the treatment and prevention of rare but growing non-tuberculous mycobacterial infections.
- RENARCI: network dedicated to clinical trials against severe bacterial infections and antibiotic resistance.
These six new networks were selected following a labeling campaign launched in July 2024 and the evaluation of the dossiers of 17 candidate networks. This evaluation was carried out by the F-CRIN Scientific Council, chaired by Pr Cristina Sampaïo and co-chaired by Pr Christian Ohmann. The deliberations were then submitted to the Governance Board, which brings together representatives from hospitals, academia, industry and patient associations, who ratified the labeling of these seven new networks.
.
"With the integration of these six new nationwide networks, we are strengthening our ability to structure French clinical research in strategic, rare or emerging fields. Each network provides a concrete response to major healthcare challenges, as close as possible to patients, caregivers and innovation. They will benefit fully from the support and scientific and operational dynamism of F-CRIN, a model recognized for its efficiency and its contribution to making France a key player in clinical research on an international scale." comments Prof. Olivier Rascol, coordinator of F-CRIN.
Thanks to the F-CRIN label, these new networks will be able to draw on the full scientific, operational and collaborative power of the infrastructure, and benefit from:
- Funding for human resources and operating costs;
- The provision of operational tools (steering tools, shared databases, active patient files, validated procedures, ...) ;
- Targeted training in clinical research on themes of major importance to biomedical research ;
- Information and communication tools (brochures, website, events, press relations) ;
- Administrative, financial and legal support ;
- European visibility thanks to direct access to the European ECRIN infrastructure, for the extension to Europe of French-coordinated clinical projects, and the participation of French teams in multinational studies;
- And above all, the collective intelligence, feedback and dynamics of the F-CRIN network.
In total, since its inception, F-CRIN has participated in over 800 clinical research projects, 41% of which were international in scope, and initiated over 2,500 scientific publications. The national coordination and the various components benefit from the support of several university hospitals, universities, foundations and industrial partners. For further information: https://www.fcrin.org/
About networks
F-MOM (French Maternal Outcomes Monitoring) is a national network dedicated to clinical research in maternal health, led by Dr. Aude Girault (Cochin-Port Royal Hospital - AP-HP, Inserm) & Dr. Catherine Deneux (Inserm). A spin-off from the GROG (Groupe de Recherche en Obstétrique et Gynécologie) network, F-MOM brings together 30 maternity units and 14 clinical investigation centers (CICs) throughout France. Its ambition is to produce high-impact data on serious maternal complications, medication safety during pregnancy and women's experience, by integrating innovative approaches (real-life data, artificial intelligence, Patient-Reported Outcomes (PROs). In this way, F-MOM aims to fill current gaps in research, notably due to the frequent exclusion of pregnant women from clinical trials, and to contribute to the development of care practices and national recommendations.
GRACE (Group for Research on Amyloidosis and Care Excellence) is a structuring national network dedicated to clinical research, innovation and improved care in amyloidosis, a rare and serious disease caused by the abnormal accumulation of amyloid proteins in tissues and organs, which progressively disrupt their function, in particular cardiac amyloidosis. Coordinated by Profs Thibaud Damy, Erwan Donal and Olivier Lairez, GRACE federates 39 centers around the national HEAR registry (>8,500 patients) and an integrated ecosystem including biobanks, imaging, clinical trials, artificial intelligence and patient associations. The network draws on strong multidisciplinary expertise (cardiology, hematology, neurology, general medicine, etc.) to develop an early, personalized and collaborative approach to this rare, under-diagnosed and potentially lethal disease. GRACE aims to position France as a European leader in the field of amyloidosis.
CONDOR (COllaborative Network for the Detection, management and peRsonalization Of care in chronic Respiratory diseases) is a national clinical research network dedicated to the study of COPD (chronic obstructive pulmonary disease), a chronic, progressive and irreversible respiratory disease affecting the bronchi and lungs, which is still too often under-diagnosed. Coordinated by Prof. Nicolas ROCHE (Cochin-Port Royal Hospital - AP-HP), CONDOR federates clinical, epidemiological and translational teams around three strategic axes: early detection, phenotyping and personalized medicine. Thanks to a structured network of experts, national cohorts and European collaborations, it aims to improve the prevention, assessment and individualized management of COPD, by integrating real-life data, biomarkers, artificial intelligence and patient feedback, in a dynamic of innovation and impact on public health.
.
Launched in 2025, FAMIREA (Advancing Family-Centred Care in the ICU) is a national network dedicated to research into support for relatives of intensive care patients. Coordinated by Prof. Elie AZOULAY (Paris Cité University, AP-HP, Inserm) and Dr Nancy Kentish-Barnes (Sociologist), it brings together 62 intensive care units in France. FAMIREA is developing a multidisciplinary approach combining clinical research, social sciences, mental health, health economics and digital technologies to understand, prevent and treat psychological disorders (particularly post-traumatic stress disorder) in relatives. With over 35 projects to its credit, and a strong ethical and societal base, FAMIREA aims to transform care practices in intensive care by putting the family back at the heart of support, while influencing public health policies and national and international recommendations.
Myco-NET is the first structured national network dedicated to clinical research into non-tuberculous mycobacterial infections (NTM), rare, chronic and rapidly progressing pathologies that are often poorly understood and difficult to treat. Coordinated by Profs Claire ANDREJAK (Amiens-Picardie University Hospital) and Nicolas VEZIRIS (AP-HP, Sorbonne University), the network federates 46 hospitals and 30 CICs, bringing together clinicians, microbiologists, researchers in biomarkers, environment, immunology, genetics and therapeutic development. Myco-NET relies on multi-center trials already underway (CaMoMy, CLAZI, AKAPI), industrial and associative partnerships, and rigorous governance to develop new diagnostic, therapeutic and preventive strategies. Its aim is to structure a national and European response to these serious infections, which are still largely underestimated.
RENARCI (REseau NAtional de Recherche Clinique en Infectiologie) is a national network of excellence dedicated to clinical research into frequent and/or serious bacterial infections, such as urinary tract infections, osteo-articular infections, endocarditis, septicemia and antibiotic resistance. Coordinated by Prof. Louis Bernard (University of Tours), RENARCI brings together infectiologists, microbiologists, methodologists and clinicians from over 90 hospitals. The network relies on solid governance, an internal ethics committee, an ISO 9001-certified quality platform, and expert support for project submissions. With over 9,800 patients enrolled in trials over the last five years, and a strong dynamic of national and international collaboration, RENARCI aims to accelerate the development of innovative strategies to address major public health challenges in infectious diseases.
Press contact : EVE'VOTREDIRCOM - servicepresse@votredircom.fr - 06 62 46 84 82
